Matinas Biopharma (MTNB) Competitors $0.87 +0.10 (+13.38%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$0.81 -0.06 (-7.22%) As of 05/16/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MTNB vs. CLDI, RLYB, NKGN, HOTH, NXTC, IMNN, NERV, BCTX, BGXX, and CLRBShould you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include Calidi Biotherapeutics (CLDI), Rallybio (RLYB), NKGen Biotech (NKGN), Hoth Therapeutics (HOTH), NextCure (NXTC), Imunon (IMNN), Minerva Neurosciences (NERV), BriaCell Therapeutics (BCTX), Bright Green (BGXX), and Cellectar Biosciences (CLRB). These companies are all part of the "pharmaceutical products" industry. Matinas Biopharma vs. Calidi Biotherapeutics Rallybio NKGen Biotech Hoth Therapeutics NextCure Imunon Minerva Neurosciences BriaCell Therapeutics Bright Green Cellectar Biosciences Calidi Biotherapeutics (NYSE:CLDI) and Matinas Biopharma (NYSE:MTNB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, community ranking, profitability, media sentiment, valuation and analyst recommendations. Which has more risk and volatility, CLDI or MTNB? Calidi Biotherapeutics has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Matinas Biopharma has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Do analysts rate CLDI or MTNB? Calidi Biotherapeutics currently has a consensus price target of $10.00, indicating a potential upside of 2,339.02%. Given Calidi Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Calidi Biotherapeutics is more favorable than Matinas Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to CLDI or MTNB? In the previous week, Calidi Biotherapeutics had 3 more articles in the media than Matinas Biopharma. MarketBeat recorded 3 mentions for Calidi Biotherapeutics and 0 mentions for Matinas Biopharma. Calidi Biotherapeutics' average media sentiment score of 0.23 beat Matinas Biopharma's score of 0.00 indicating that Calidi Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Calidi Biotherapeutics Neutral Matinas Biopharma Neutral Which has preferable valuation and earnings, CLDI or MTNB? Matinas Biopharma has higher revenue and earnings than Calidi Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalidi Biotherapeutics$50K233.44-$29.22MN/AN/AMatinas Biopharma$1.10M4.04-$22.94M-$5.03-0.17 Do institutionals and insiders believe in CLDI or MTNB? 12.5% of Calidi Biotherapeutics shares are held by institutional investors. Comparatively, 11.8% of Matinas Biopharma shares are held by institutional investors. 24.3% of Calidi Biotherapeutics shares are held by company insiders. Comparatively, 6.0% of Matinas Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is CLDI or MTNB more profitable? Calidi Biotherapeutics' return on equity of 0.00% beat Matinas Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Calidi BiotherapeuticsN/A N/A -344.45% Matinas Biopharma N/A -123.06%-94.28% Does the MarketBeat Community believe in CLDI or MTNB? Calidi Biotherapeutics and Matinas Biopharma both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformCalidi BiotherapeuticsN/AN/AMatinas BiopharmaN/AN/A SummaryCalidi Biotherapeutics beats Matinas Biopharma on 10 of the 13 factors compared between the two stocks. Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTNB vs. The Competition Export to ExcelMetricMatinas BiopharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$4.44M$6.45B$5.36B$19.67BDividend YieldN/A2.65%4.94%3.85%P/E Ratio-0.189.1627.0435.55Price / Sales4.04248.23390.4735.62Price / CashN/A65.8538.2517.51Price / Book0.206.456.764.78Net Income-$22.94M$143.73M$3.23B$1.02B7 Day Performance23.83%4.48%4.83%3.48%1 Month Performance48.72%7.84%9.88%10.69%1 Year PerformanceN/A-4.99%15.35%5.45% Matinas Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTNBMatinas BiopharmaN/A$0.87+13.4%N/AN/A$4.44M$1.10M-0.1830Gap DownHigh Trading VolumeCLDICalidi Biotherapeutics1.9744 of 5 stars$0.44-3.3%$15.00+3,279.9%N/A$12.63M$50,000.000.0038News CoverageGap DownRLYBRallybio1.9199 of 5 stars$0.30+2.7%$10.00+3,223.4%-80.2%$12.52M$636,000.00-0.1940News CoverageGap UpNKGNNKGen BiotechN/A$0.28+61.4%N/A-68.8%$12.41M$80,000.00-0.05N/AHOTHHoth Therapeutics3.3119 of 5 stars$0.93-2.5%$4.00+330.5%-27.1%$12.24MN/A-0.704Earnings ReportGap DownNXTCNextCure4.0269 of 5 stars$0.43-2.6%$3.50+705.9%-73.8%$12.18MN/A-0.2190Gap UpIMNNImunon1.8359 of 5 stars$0.82+2.0%$21.50+2,535.1%-65.4%$11.93M$500,000.00-0.4330News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpNERVMinerva Neurosciences3.617 of 5 stars$1.66+2.9%$5.00+201.9%-40.5%$11.58MN/A-3.769Earnings ReportAnalyst ForecastGap UpBCTXBriaCell Therapeutics1.4595 of 5 stars$3.12+0.3%$32.00+925.6%-85.9%$11.57MN/A-0.238BGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap DownCLRBCellectar Biosciences2.3843 of 5 stars$0.26+6.8%$12.50+4,633.1%-92.6%$11.40MN/A-0.1510Earnings ReportAnalyst Revision Related Companies and Tools Related Companies CLDI Alternatives RLYB Alternatives NKGN Alternatives HOTH Alternatives NXTC Alternatives IMNN Alternatives NERV Alternatives BCTX Alternatives BGXX Alternatives CLRB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MTNB) was last updated on 5/19/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MTNB Stock Free MTNB Stock Alerts